官方服务：
资源简介：
Treatment time on EGFR TKIs.
应用场景：
创建时间：
2018-11-27
相关数据集
Unique microRNA profiles in EGFR-mutated lung adenocarcinomas
We have examined the microRNA expression in 154 lung adenocarcinoma samples and 20 paired normal lung tissue samples and investigated the microRNA expression to clinical variables, EGFR- and KRAS- mut
NIAID Data Ecosystem100
DataSheet_1_c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma.docx
c-Src and the epidermal growth factor receptor (EGFR) are key apical kinases that govern cell responses to microenvironmental cues. How c-Src affects EGFR-related signaling and targeted therapy remain
NIAID Data Ecosystem40
Dataset from Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
NIAID Data Ecosystem30
Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response
Lung cancers bearing oncogenically-mutated EGFR represent a significant fraction of lung adenocarcinomas (LUADs) for which EGFR-targeting tyrosine kinase inhibitors (TKIs) provide a highly effective t
NIAID Data Ecosystem60
Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
Adenocarcinoma is the most common type of non-small cell lung cancer. Some causative genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon 19 (E19 dels) and a poi
NIAID Data Ecosystem30
